Table 5.

Clinical trials in patients with ≥ 3 lines of treatment.

Treatment	No. of Patients	Overall Response %	PFS—HR	PFS—Months	OS—Months	Grade ≥ 3 AE %	Median (Range) of Prior Lines of Therapy	Trial Name
IsaPd vs. Pd	307	60 vs. 35	0.59	11.5 vs. 6.5	NR	NA	3 (2−4)	ICARIA [69]
EloPd vs. Pd	117	53 vs. 26	0.54	10.3 vs. 4.7	NR	57 vs. 60	3 (2−8)	ELOQUENT 3 [70]
DPd	103	66	NA	9.9	25.1	99	4 (1−13)	EQUULEUS [71]

Abbreviations: PFS, Progression free survival; HR, Hazard ratio; OS, Overall survival, AE, Adverse events; NR, Not reached; NA, Not available; IsaPd: Isatuximab, pomalidomide, dexamethasone; Pd: Pomalidomide, dexamethasone; EloPd: Elotuzumab, pomalidomide, dexamethasone; DPd: Daratumumab, pomalidomide, dexamethasone.